Patients were randomly assigned to bevacizumab with paclitaxel 90 mg/m ( 2 ) ( arm A ) , nab-paclitaxel 150 mg/m ( 2 ) ( arm B ) , or ixabepilone 16 mg/m ( 2 ) ( arm C ) , once per week for 3 of 4 weeks .